Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Recruiting · New Haven, Connecticut
Always free
Study care at no cost to you
For your time and travel
Many studies pay you back
Most need no insurance or papers
Legal status usually isn't required; we'll tell you each study's requirements
Interpreters available
Ask for your language
Your choice
Voluntary — you can stop anytime
What is this study?
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events.
It is , overseen by an independent and licensed medical staff.
Read the full clinical description
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.
Who this study is looking for
In plain language, from the study's own rules. The study team confirms the full details with you — this isn't a final yes or no.
✅ You may be able to join if…
- •Be age 18 to 30 and have type 1 diabetes (T1D) with a qualifying BMI for anti-obesity treatment (BMI ≥30 alone, or BMI ≥27 with a weight-related condition).
- •Have a type 1 diabetes diagnosis for at least 12 months.
- •Have HbA1c ≤10% at screening and within the past 90 days (HbA1c shows average blood sugar over time).
- •Have stable insulin dosing for the past 90 days (within 15%).
- •Be able to use real-time continuous glucose monitoring and agree to continue it during the study.
🚫 You may not be able to join if…
- •Use GLP-1 medicines or other diabetes/anti-obesity medicines now or within the past 6 months.
- •Have insulin dosing below 0.5 units/kg/day.
- •Have a current psychiatric condition that affects weight, including a known eating disorder.
- •Have certain safety issues (for example: creatinine ≥1.0 mg, triglycerides ≥400 mg/dl, or ALT ≥3.5× the upper normal limit).
- •Be pregnant or breastfeeding, or plan pregnancy, or not use adequate birth control; also cannot join with diabetic ketoacidosis in the past 6 months or severe hypoglycemia requiring hospitalization in the past 3 months.
Are you a good fit?
Simplified highlights. The study team always confirms the full details with you.
- ✓Adults roughly 18–30
- ✓A BMI around 30 or higher
- ✓Have Obesity / overweight
- !Some conditions may not be a fit: Kidney disease
- !Not for people who are pregnant or breastfeeding
- !May require a break from current GLP-1 medications
What to expect, step by step
- 1
Usually a few weeks
The study team checks whether the study is a good fit for you, with a visit and sometimes lab tests. You can ask any questions before deciding.
- 2
Treatment
If you join and choose to continue, you receive the study treatment and are watched closely by medical staff.
- 3
Follow-up
After treatment, the team checks on your health and confirms the visit schedule with you. You can leave the study at any point.
Has this treatment been tested before?
Yes. This treatment has already been through earlier human studies for safety before reaching this stage.
What you need to know before you apply
What is this study testing?+
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events.
Is it safe? Who makes sure of that?+
This is a mid-stage study (Phase 2), looking at safety and whether the treatment works. Every study is reviewed and monitored by an independent ethics board (called an IRB) whose job is to protect participants, and care is overseen by licensed medical staff. You'll be told the known risks before you agree to anything, and you can stop at any time.
Will I get a placebo instead of the real treatment?+
Some studies compare a treatment against a placebo (an inactive version), and some don't. If this one does, the study team will explain your chances of receiving the active treatment before you decide. Nothing is hidden from you.
I take a GLP-1 medication (like Ozempic or Wegovy). Can I still join?+
Maybe. This study may ask you to pause certain weight or diabetes medications for a period of time (a 'washout') before joining, or it may be looking for people not currently on them. The coordinator will review your medications with you — don't stop any medication on your own.
Does it cost anything? Will I be paid?+
The study treatment and study-related visits are provided at no cost to you. Some studies also pay for your time; the coordinator can tell you if this one does. You should never be asked to pay to take part.
Do I need insurance? Will anyone ask about my immigration status?+
No. You do not need health insurance to take part in a research study, and you will not be asked about your immigration status to join. Taking part is about whether you're a medical fit for the study.
What if English isn't my first language?+
You have the right to understand everything before you agree. Study sites can often provide materials or an interpreter in your language — you can ask the coordinator for one.
Is my information private?+
Yes. Your health information is only shared with the study sites you choose to be contacted by, and only to help match and enroll you. It is never sold, and you can ask us to delete it at any time.
Some requirements (like specific lab values or timing) are confirmed directly by the study team, not by us.
Source: ClinicalTrials.gov · NCT06411210 · Locations: Connecticut